SCHEMBL7120572

SCHEMBL7120572

N#Cc1ccc(Oc2ccc(C(=O)N[C@@H]3C[C@H]4CC[C@@H]3N4)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.49
RAB9A P51151 2/20 0.48
NPC1 O15118 1/20 0.48
PARP15 Q460N3 1/20 0.46
PARP10 Q53GL7 1/20 0.46
PARP2 Q9UGN5 1/20 0.46
MMP2 P08253 1/20 0.46
MMP7 P09237 1/20 0.46
MMP9 P14780 1/20 0.46
MMP13 P45452 1/20 0.46
SCN9A Q15858 9/20 0.42
LMNA P02545 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
PKM P14618 1/20 0.42
MAPK1 P28482 1/20 0.42
KMT2A Q03164 1/20 0.42
IL18 Q14116 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7121133 0.91 SLC6A2 (0.47) EPHX2RAB9ANPC1MMP2MMP7
SCHEMBL7121263 0.89 EPHX2 (0.42) EPHX2RAB9ANPC1SCN9APOLB
SCHEMBL7125203 0.89 EPHX2 (0.40) EPHX2RAB9ANPC1MMP2MMP7
SCHEMBL7123432 0.87 MMP2 (0.39) EPHX2RAB9ANPC1MMP2MMP7
SCHEMBL7124896 0.87 MMP2 (0.57) NPC1MMP2MMP7MMP9MMP13
SCHEMBL7120658 0.87 MMP2 (0.45) PARP10MMP2MMP7MMP9MMP13
SCHEMBL7127352 0.87 EPHX2 (0.40) EPHX2RAB9ANPC1PARP15PARP10
SCHEMBL7124883 0.87 EPHX2 (0.40) EPHX2RAB9ANPC1PARP15PARP10
SCHEMBL7125131 0.86 EPHX2 (0.49) EPHX2RAB9ANPC1LMNAALDH1A1
SCHEMBL7122473 0.86 EPHX2 (0.39) EPHX2RAB9ANPC1MMP2MMP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US claimed
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease CYP7B1, UGT2B7, CYP1B1 EPHX2 194/4885RAB9A 491/4885NPC1 267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.